FindTrial
Sign In

Efficacy of injectable platelet rich fibrin in tempromandibular joint disorders.

Comparative evaluation of the role of injectable platelet rich fibrin with Diclofenac Sodium in patients with temporomandibular disorders - a randomized controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045320
Enrollment
30
Registered
2022-09-07
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M266- Temporomandibular joint disorders

Interventions

Intervention1: Injectable platelet rich fibrin: i-PRF injection of 2 ml in each joint . Control Intervention1: Diclofenac Sodium: 50 mg tablet BD ( twice a day ) for 14 days

Sponsors

Aishla Jain
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with internal derangement of TMJ disorders classified under Wilkes stage II, III, IV and V.

Exclusion criteria

Exclusion criteria: Autoimmune diseases 1.Benign or malignant temporomandibular joint lesions 2.Neurological disorders, 3. Blood diseases and coagulation disorders 4. Allergies or anaphylactic shock. 5. History of peptic ulcers.

Design outcomes

Primary

MeasureTime frame
Assessment of painâ??VISUAL ANALOGUE SCALE.Timepoint: 0 day , 14 days 30 days , 60 days , 90 days—

Secondary

MeasureTime frame
1) The range of mandibular motion (maximum unassisted opening (MUO), maximum assisted opening (MAO), protrusive movement (PM), right lateral excursion (RLE) and left lateral excursion (LLE) 2) Tenderness of masticatory muscle â?? by manual palpation 3) Clicking soundTimepoint: 0 day , 14 days 30 days , 60 days , 90 days—

Countries

India

Contacts

Public ContactAishla Jain

PGIMER

drvidyarattan@gmail.com9914900871

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026